GHDDI and Microsoft Research Scientific Intelligence Center have reached a cooperation to jointly empower the research and development of new drugs through AI.

##Editor | The Academy's Scientific Intelligence Center (Microsoft Research AI4Science) announced a cooperation. The two parties will jointly develop generative artificial intelligence and basic large model technology in the field of global health infectious diseases, focusing on implementation and transformation, and accelerating the research and development of innovative drugs. Previously, the two parties have successfully designed a variety of small molecule inhibitors with new structures in the research on key target proteins of Mycobacterium tuberculosis and coronavirus.

The launching ceremony of the cooperation between the Global Health Drug Research and Development Center and the Microsoft Research Scientific Intelligence Center can be rewritten as: The Global Health Drug Research and Development Center and the Microsoft Research Scientific Intelligence Center The cooperation launching ceremony

Based on the concept of open innovation, the Global Health Drug Research and Development Center aims to cooperate with the Scientific Intelligence Center of Microsoft Research to use artificial intelligence technology to efficiently empower the research and development of new drugs and bring them to patients around the world as soon as possible. Safer and more effective pharmaceutical solutions to promote global health equity. The collaboration focuses on addressing infectious diseases that threaten global health, such as tuberculosis, viral infections and malaria. The cooperation will deeply integrate generative artificial intelligence, basic large model technology, virtual high-throughput screening and expert experience. At the same time, it will rely on the new drug research and development capabilities and innovative transformation technology platform of the Global Health Drug Research and Development Center to realize the virtual generation and screening of compounds to synthesis. and optimization, and then to biological experimental verification, and finally realize a complete "dry and wet closed-loop" process of iterative upgrading of artificial intelligence to improve the efficiency of new drug research and development

Dr. Ding Sheng, director of the Global Health Drug Research and Development Center (GHDDI), delivered a speech

Dr. Ding Sheng, director of the Global Health Drug Research and Development Center, said: "In today's scientific research field, we are facing unprecedented challenges. challenges, but also unprecedented opportunities. Innovation is the core driving force for scientific progress and a key factor in solving global health problems. I am deeply excited about the cooperation with Microsoft Research and at the same time happy for the progress made by both parties. Working together will undoubtedly improve research and development efficiency and accelerate the process of new drug research and development. This is a 'cross-border' and 'leapfrogging' cooperation. The collaboration between the two parties will promote the continuous advancement of pharmaceutical research and open up new paths for scientific research. In the future, we expect Such cutting-edge technologies can be widely applied to unknown areas in life sciences to provide more comprehensive, in-depth and feasible solutions to health problems around the world."

Dr. Liu Tieyan, Microsoft Distinguished Chief Scientist and Asia Head of the Microsoft Research Scientific Intelligence Center, delivered a speech

As a cross-regional and cross-domain global team, the Microsoft Research Scientific Intelligence Center is committed to exploring the intersection of machine learning and natural sciences. Basic research in the field has made progress, fundamentally changing the way humans understand and interact with the natural world. Dr. Liu Tieyan, Asia head of the Scientific Intelligence Center of Microsoft Research, said: "The development of AI drug discovery requires in-depth cooperation between AI experts and medical experts. Microsoft Research has the world's top technology and has conducted research at the intersection of AI and natural sciences. In-depth research. The experts at the Global Health Drug R&D Center have rich industry experience and in-depth domain knowledge. Their advanced experimental facilities provide reliable support for our compound synthesis and performance testing, providing valuable information for the training of AI models. Feedback. Through strong alliances and close cooperation, we will go further on the road of AI pharmaceuticals, achieve more disruptive research results, and reshape the future of medical health with AI technology innovation."

## The data science platform of #Global Health Drug R&D Center works closely with the Scientific Intelligence Center of Microsoft Research. Based on the published data, it combines the physical and chemical properties and structural properties of molecules with the artificial intelligence generation model framework, and uses the data obtained in the actual drug development process. Experimental data fine-tunes the pre-trained model to generate a new virtual compound library with high affinity and structural diversity for the active site of a specific biological target protein, which is then screened through a virtual screening process based on physics simulation and deep learning technology and drug-likeness evaluation criteria. Candidate molecules with potential biological activity. Subsequently, the medicinal chemistry team carried out molecular modification and synthesis of the screened compounds, and verified them through biological experiments.

It is worth mentioning that in the research on Mycobacterium tuberculosis and coronavirus respectively, the joint team of both parties has used this innovative generative AI new drug development process to target these pathogens in just half a year. A variety of effective and novel small molecule inhibitors of key target proteins have been successfully designed. These compounds performed well in enzyme inhibition experiments, and their inhibitory potency even exceeded that of currently known lead compounds.

Dr. Zhang Rumin, chief scientific officer of the Global Health Drug Research and Development Center, said: "Compared with the long process of traditional drug research and development, the teams from both parties successfully designed a drug for the drug within three to five months through this new artificial intelligence technology. These pathogens have highly effective small molecule inhibitors, and they have completely new molecular structures. This is a remarkable achievement, which demonstrates the great potential of AI in highly efficient de novo drug design. At the same time, it fully reflects the team's excellent innovation ability and professional strength. We look forward to this innovative R&D strategy bringing more breakthroughs in a wider range of drug R&D projects in the future."

Dr. Qin Tao is Microsoft Research Senior Principal Investigator of the Academy’s Center for Scientific Intelligence. He said that the combination of Microsoft Research's large-scale models and generative AI technology with the professional drug research and development capabilities and industry experience of the Global Health Drug Research and Development Center jointly contributed to the discovery of these highly effective small molecule inhibitors. The achievement of this result is very exciting. In the future, they will continue to deepen this cooperation, promote the application of AI technology in the field of new drug research and development, use AI innovation to promote human health, solve global health challenges, and let the benefits of AI technology benefit everyone

Dr. Guo Jinjiang, head of the data science department of the Global Health Drug Research and Development Center (GHDDI), delivered a keynote speech

Dr. Guo Jinjiang, head of the data science department of the Global Health Drug Research and Development Center, said: “In the future, we will continue to strengthen and expand cooperation, further promote the depth of application of artificial intelligence technology in the field of life sciences, provide scientific researchers with new discoveries and new perspectives on life mechanisms, and thereby output innovative treatment strategies to solve long-term problems. Provide more effective solutions to diseases of human health. We are full of expectations for the prospects of this cooperation and believe that it will play an important role in the future health field."

About Global Health Drugs R&D Center

In 2016, the Bill & Melinda Gates Foundation, Tsinghua University and the Beijing Municipal Government jointly established the Global Health Drug Research and Development Center (GHDDI). GHDDI is China's first non-profit innovative drug research and development institution established using the PPP (Government and Social Capital Partnership) model. It is committed to responding to major disease challenges in the global health field and developing innovative drugs and new technologies. GHDDI focuses on translational research from laboratory to clinic, with focus on antiviral research as well as tuberculosis, malaria and other fields

For more information about GHDDI, please visit: www.ghddi. org

The above is the detailed content of GHDDI and Microsoft Research Scientific Intelligence Center have reached a cooperation to jointly empower the research and development of new drugs through AI.. For more information, please follow other related articles on the PHP Chinese website!